Caffeinated energy drinks in the Canadian context: health risk assessment with a focus on cardiovascular effects.


Journal

Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme
ISSN: 1715-5320
Titre abrégé: Appl Physiol Nutr Metab
Pays: Canada
ID NLM: 101264333

Informations de publication

Date de publication:
Sep 2021
Historique:
pubmed: 18 5 2021
medline: 21 12 2021
entrez: 17 5 2021
Statut: ppublish

Résumé

In Canada, caffeinated energy drinks (CEDs) currently sold under Temporary Marketing Authorizations must meet strict eligibility criteria. These criteria, which include compositional and labelling requirements, were developed based on the outcome of a health risk assessment conducted by Health Canada (HC) in 2013. HC updated its assessment by reviewing new information with the focus on potential cardiovascular effects associated with the consumption of CEDs available for sale in Canada. Due to limited data on CED consumption among Canadians to derive accurate exposure information, the composition of a typical CED was characterized to assess the potential effects of single ingredients and synergistic interactions between ingredients on the cardiovascular system. Surveillance data on potential adverse effects related to CED consumption was also analyzed. After extensive review, HC's updated assessment confirms the current risk management approach for CEDs is health protective for Canadian consumers, including the potential for cardiovascular effects. The available evidence supports that moderate consumption (up to 500 mL per day) of a typical CED authorized for sale in Canada is safe for the general population of healthy adults and adolescents. It also re-confirms that vulnerable sub-populations (i.e., children, pregnant and/or breastfeeding women, and caffeine-sensitive individuals) should not consume CEDs.

Identifiants

pubmed: 34000209
doi: 10.1139/apnm-2021-0245
doi:

Substances chimiques

Central Nervous System Stimulants 0
Glucuronates 0
Vitamin B Complex 12001-76-2
Taurine 1EQV5MLY3D
glucuronolactone 32449-92-6
Caffeine 3G6A5W338E
Inositol 4L6452S749

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1019-1028

Auteurs

Sébastien La Vieille (S)

Bureau of Chemical Safety, Food Directorate, Health Canada, Ottawa, ON, Canada.

Zoe Gillespie (Z)

Bureau of Chemical Safety, Food Directorate, Health Canada, Ottawa, ON, Canada.

Yvette Bonvalot (Y)

Biostatistics and Modelling Division, Bureau of Food Surveillance and Science Integration, Food Directorate, Health Canada, Ottawa, ON, Canada.

Karima Benkhedda (K)

Bureau of Nutritional Sciences, Food Directorate, Health Canada, Ottawa, ON, Canada.

Nancy Grinberg (N)

Bureau of Nutritional Sciences, Food Directorate, Health Canada, Ottawa, ON, Canada.

Joel Rotstein (J)

Bureau of Chemical Safety, Food Directorate, Health Canada, Ottawa, ON, Canada.

Jennifer Barber (J)

Bureau of Nutritional Sciences, Food Directorate, Health Canada, Ottawa, ON, Canada.

Andrew D Krahn (AD)

Center for Cardiovascular Innovation, Division of Cardiology, The University of British Columbia, Vancouver, BC, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH